Digest Network Come funziona
Network
/
Società
Fa
Non verificato

Faeth Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

10 comunicati stampa

Guarda tutti i comunicati
27/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
20/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
20/10/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
19/10/2025
Eventi
Industria
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
30/09/2025
Software
Scienza
Associazioni/Professionisti
Farmaceutica
Oncologia
Tecnica
Biotecnologia
Salute
Industria
Faeth Therapeutics’ R&D Platform Delivers First Cross-Disease Validation Beyond Oncology
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
24/09/2025
Eventi
Industria
Biotecnologia
Tecnica
Salute
Farmaceutica
Oncologia
Scienza
Software
Fitness
Medicina - Varie
Faeth Therapeutics Announces Late-Breaking Presentation of Positive Phase 2 Data in Ovarian Cancer at ESMO 2025
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
13/05/2025
Analisi di mercato
Industria
Sanità
Farmaceutica
Oncologia
Vetrine/Shopping
Fitness
Libri/Editoria
Medicina - Varie
Biotecnologia
Comunicazione
Salute
Faeth Therapeutics Shows Preclinical Proof-of-Concept for Drug-Diet Combination to Treat Cancer, in Peer-Reviewed Publication
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
12/03/2025
Multimedialità
Industria
Medicina - Varie
Associazioni/Professionisti
Biotecnologia
Salute
Vetrine/Shopping
Farmaceutica
Oncologia
Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
22/11/2024
Tecnica
Scienza
Biotecnologia
Salute
Farmaceutica
Oncologia
Mercato del lavoro
Faeth Therapeutics Appoints Dr. Stephen Hahn and Dr. Jayson Dallas to Board of Directors
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0
17/07/2024
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Eventi
Fiere
Industria
Faeth Therapeutics to Present at Raymond James Biotech Private Company Showcase
Fonte
Faeth Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0